Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Early results of PHE885, a novel BCMA-directed CAR-T therapy for the treatment of R/R MM

Nikhil Munshi • 9 Jun 2022
EHA 2022
Multiple Myeloma CAR-T PHE885

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses a Phase II study investigating PHE885, a novel BCMA-directed CAR-T therapy, for the treatment of relapsed/refractory (R/R) multiple myeloma. Dr Munshi first comments on the methods used to produce this agent, and further highlights some of the early findings of this study. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Advisory Board/Consultant: Adaptive, Abbvie, Amgen, BMS, Janssen, Karyopharm, Legend, Oncopep, Millennium, Novartis, Pfizer DCT

Scientific Founder: Oncopep, DCT

More from Nikhil Munshi

1:56
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma
Nikhil Munshi • 11 Dec 2023
1:05
Alterations to the bone marrow microenvironment in patients with AL amyloidosis
Nikhil Munshi • 11 Dec 2023
2:42
Immunotherapeutic approaches to overcoming drug resistance in venetoclax-exposed patients with MM
Nikhil Munshi • 11 Dec 2023
2:02
Updated Phase I study results of PHE885 in patients with R/R multiple myeloma
Nikhil Munshi • 9 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals